Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00317044 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma
A Phase 2 study of Asthma and GERD, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 961
- Enrollment target
- 20
- Study locations
NCT00317044: Completed Phase 2 study of Asthma and GERD, sponsored by AstraZeneca.
NCT00317044 is a Phase 2 study of Asthma and GERD that has completed, run by AstraZeneca. The registered enrollment target is 961 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00317044, a Phase 2 study of Asthma and GERD, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 961 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether treatment with esomeprazole for 6 months will improve asthma in adult patients with moderate to severe asthma and symptoms of gastroesophageal reflux disease.
Primary Outcome
Peak expiratory flow is defined as the maximum speed of expiration as measured with the Mini-Wright® PEF Meter. Participants must have both baseline and follow up measure to be included in analysis. Results presented as a mean of all available data during the treatment period.
Interventions
- DRUG Placebo
- DRUG Esomeprazole
Study Locations (20)
Georgia
- Research Site - Atlanta
- Research Site - Stockbridge
Kansas
- Research Site - Overland Park
- Research Site - Wichita
Ohio
- Research Site - Cincinnati
- Research Site - Sylvania
Pennsylvania
- Research Site - Pittsburgh
- Research Site - Upland
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Scottsdale
Arkansas
- Research Site - Little Rock
California
- Research Site - Fountain Valley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 961 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00317044 record still lists
NCT00317044 is an interventional study that assigns participants to a tested intervention. The registered 961 participants enrollment target is mid-sized for trials with a published cap, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (38% lower).
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00317044 names 20 study sites across 16 states, led by Georgia, Kansas, Ohio.
Frequently Asked Questions
What is clinical trial NCT00317044 about?
NCT00317044 is a clinical study titled "Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma". The purpose of this study is to determine whether treatment with esomeprazole for 6 months will improve asthma in adult patients with moderate to severe asthma and symptoms of gastroesophageal reflux disease.
What is the current status of trial NCT00317044?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 961 participants. The study started on 2006-04. Estimated completion is 2008-07.
What conditions does trial NCT00317044 study?
This clinical trial studies the following conditions: Asthma, GERD.
What interventions are being tested in trial NCT00317044?
The interventions under investigation include: Placebo (DRUG), Esomeprazole (DRUG).
Who is sponsoring clinical trial NCT00317044?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00317044 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00317044's enrollment target sits among peer trials
961 46th of 374 higher than 329 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia